Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
schizophrenia
Biotech
Neurocrine's bid to save schizophrenia prospect fails
The biotech was unable to replicate the cognition signal it saw in an earlier midphase study, prompting it to stop development of luvadaxistat.
Nick Paul Taylor
Sep 13, 2024 7:30am
Newron schizophrenia add-on improves positive, negative symptoms
Apr 30, 2024 9:13am
Neumora schizophrenia drug on FDA hold over rabbit convulsions
Apr 15, 2024 9:00am
BMS' schizophrenia drug shows long-term benefit with new data
Apr 6, 2024 1:15pm
Boehringer pays €25M for option to Sosei’s schizophrenia drug
Mar 11, 2024 9:10am
Minerva's schizophrenia drug rejected by FDA for 2nd time
Feb 27, 2024 9:34am
